KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 fiscal 2024 results and provided updates on sebetralstat, its investigational oral treatment for hereditary angioedema (HAE) attacks. The FDA accepted the New Drug Application with a PDUFA date of June 17, 2025. The company submitted Marketing Authorization Applications in multiple countries.

Financial highlights include pro forma cash and equivalents of $292.2 million, providing runway into second half 2027. The company raised $160 million through synthetic royalty financing and equity offerings. Q2 showed no revenue, R&D expenses of $16.6 million (down from $19.1 million), and G&A expenses of $29.2 million (up from $10.7 million) primarily due to pre-commercial activities.

Positive

• FDA acceptance of sebetralstat NDA with PDUFA date set for June 17, 2025
• Successful $160 million capital raise through royalty financing and equity offerings
• Strong cash position of $292.2 million providing extended runway into H2 2027
• Multiple international marketing authorization applications submitted

Negative

• No revenue generation in Q2
• G&A expenses increased significantly to $29.2 million from $10.7 million YoY

Insights

Financial Analyst

KalVista Pharmaceuticals demonstrates strong financial positioning with $292.2 million in pro forma cash, providing runway into 2H 2027. The successful raise of $160 million through strategic financing, including $100 million upfront from DRI Healthcare's synthetic royalty agreement, significantly strengthens the balance sheet. The company's increased G&A expenses of $29.2 million reflect strategic investment in pre-commercial activities for sebetralstat, while R&D expenses decreased to $16.6 million.

The FDA's acceptance of sebetralstat's NDA with a PDUFA date of June 2025, coupled with multiple international regulatory submissions, positions KalVista for potential multi-market commercialization. The company's focus on commercial infrastructure development and global market access strategy indicates strong preparation for product launch.

Medical Research Analyst

The clinical data presented for sebetralstat shows promising therapeutic value in HAE treatment. Key findings demonstrate correlation between early treatment and shorter attack duration, with comparable efficacy to IV recombinant C1-inhibitor treatments. The oral administration route represents a significant advancement over injectable therapies, potentially improving treatment adherence and reducing anxiety associated with current options.

The potential to be the first oral on-demand treatment for HAE attacks represents a significant market opportunity. The multiple regulatory submissions across major markets (US, UK, EU, Switzerland, Australia and Singapore) suggest confidence in the clinical data package and could lead to rapid market penetration following approvals.

–Continuing to build commercial infrastructure; on track for potential sebetralstat launch in Q2 2025–

–Multinational regulatory submissions for sebetralstat position Company to transform hereditary angioedema (HAE) treatment worldwide–

–Pro forma cash and cash equivalents of $292.2 million provide runway into second half 2027–

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for hereditary angioedema (HAE).

“KalVista is successfully executing on the key milestones we announced at the beginning of our fiscal year as we move towards multiple potential commercial launches of sebetralstat in 2025,” said Ben Palleiko, Chief Executive Officer of KalVista. “With six marketing authorization applications filed to date and the first potential approval expected next June, we remain focused on achieving our goal of making sebetralstat available to people living with HAE globally. In support of that goal, during the quarter, we presented additional data from our clinical program at multiple conferences, demonstrating that patients used sebetralstat to treat attacks early and that early treatment with on-demand therapy resulted in meaningful clinical benefit. Finally, the additional capital we recently raised, including the non-dilutive synthetic royalty financing, will support our continued planning for the potential launch of sebetralstat in multiple markets.”

Second Fiscal Quarter and Recent Business Highlights:

Sebetralstat

• In September 2024, KalVista announced that the FDA accepted its NDA for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor that has the potential to be the first and only oral on-demand treatment for HAE attacks in people aged 12 years and older. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of June 17, 2025.
• Also in September, KalVista announced Marketing Authorization Application (MAA) submissions to regulatory authorities in the United Kingdom, Switzerland, Australia and Singapore via the Access Consortium framework, designed to maximize regulatory collaboration across countries and support a timely review process. This follows the August European Medicines Agency (EMA) validation of the MAA for sebetralstat.
• KalVista presented new sebetralstat data at the 2024 American College of Allergy Asthma and Immunology. Presentations included Phase 3 trial data that showed early treatment is correlated with shorter attack duration, as well as a rigorous comparison of Phase 3 results for oral sebetralstat and pivotal trial results of IV recombinant C1-inhibitor for on-demand treatment of HAE attacks that showed no differences in time to the beginning of symptom relief.
• In addition, KalVista presented new data at the 2024 HAEi Global Angioedema Forum that highlighted the effectiveness of sebetralstat in reducing anxiety during HAE attacks and underscored the importance of having an oral, on-demand treatment option that could help people manage attacks earlier and more frequently. Patient perspectives shared at the forum also reinforced the high prevalence of anxiety associated with the use of injectable therapies, further supporting the call for more accessible oral alternatives.

Organizational

• In November, KalVista raised a total of $160 million in aggregate gross proceeds through concurrent synthetic royalty financing and equity offerings. The synthetic royalty financing agreement with DRI Healthcare provides up to $179 million in non-dilutive funding, including $100 million upfront. In addition, the Company closed a public offering raising $55 million as well as $5 million in a private placement to DRI Healthcare.
• The Company appointed Brian Piekos as Chief Financial Officer.

Second Fiscal Quarter Financial Results

• The Company did not record any revenue for the three months ended October 31, 2024 or three months ended October 31, 2023.
• Research and development expenses were $16.6 million for the three months ended October 31, 2024, compared to $19.1 million for the same period in the prior fiscal year. The decrease was primarily attributable to reduced preclinical activities and recognizing expense associated with sebetralstat pre-commercial awareness within General & Administrative.
• General and administrative expenses were $29.2 million for the three months ended October 31, 2024, compared to $10.7 million for the same period in the prior fiscal year. The increase was primarily due to pre-commercial planning activities related to sebetralstat.
• As of October 31, 2024, the Company had cash, cash equivalents and marketable securities of approximately $135.8 million ($292.2 million, on a pro forma basis, including the approximately $156.4 million net proceeds raised in November 2024 through the synthetic royalty financing and equity offerings). The Company anticipates that this pro forma balance provides sufficient runway into the second half of 2027.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet needs. Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date of June 17, 2025. We have also completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other countries. For more information, please visit www.kalvista.com or follow us on social media at @KalVista and LinkedIn.

About Sebetralstat

Discovered and developed entirely by KalVista, sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). Our initial goal is to deliver sebetralstat as the first oral, on-demand treatment for HAE in people aged 12 years and older. In addition, we are studying the potential of sebetralstat for the on-demand treatment of HAE in children aged 2 to 11 years. We believe that, if approved, sebetralstat has the potential to become the foundational therapy for HAE disease management globally.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

KalVista Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
	October 31,			April 30,
	2024			2024
Cash, Cash Equivalents & Marketable Securities	$	135,776		$	210,401
Other Current Assets		16,491			15,289
Total Current Assets		152,267			225,690
Other Assets		8,564			9,714
Total Assets	$	160,831		$	235,404
Current Liabilities		22,164			22,807
Long-term Liabilities		4,675			6,015
Total Liabilities		26,839			28,822
Total Stockholders’ Equity		133,992			206,582
Total Liabilities and Stockholders' Equity	$	160,831		$	235,404

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(Unaudited)
	Three Months Ended								Six Months Ended
	October 31,								October 31,
	2024				2023				2024				2023
Operating expenses:
Research and development		16,610				19,089				43,225				38,396
General and administrative		29,201				10,657				46,801				20,443
Total operating expenses		45,811				29,746				90,026				58,839
Operating loss		(45,811	)			(29,746	)			(90,026	)			(58,839	)
Other income:
Interest income		1,357				776				3,050				1,699
Foreign currency exchange rate (loss) gain		67				(1,299	)			581				(843	)
Other income		2,119				2,619				3,685				5,016
Total other income		3,543				2,096				7,316				5,872
Net loss	$	(42,268	)		$	(27,650	)		$	(82,710	)		$	(52,967	)
Net loss per share, basic and diluted	$	(0.91	)		$	(0.80	)		$	(1.78	)		$	(1.54	)
Weighted average common shares outstanding, basic and diluted		46,695,220				34,565,955				46,464,099				34,490,090

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205552223/en/

Media:

Jenn Snyder

Vice President, Corporate Affairs

(857) 356-0479

jennifer.snyder@kalvista.com



Investors:

Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

When is the PDUFA date for KalVista's (KALV) sebetralstat?

The FDA has set a PDUFA goal date of June 17, 2025 for sebetralstat, KalVista's oral treatment for HAE attacks.

How much cash does KalVista (KALV) have after recent financing?

KalVista has pro forma cash and cash equivalents of $292.2 million, following the November 2024 financing rounds.

What were KalVista's (KALV) Q2 2024 R&D expenses?

R&D expenses were $16.6 million for Q2 2024, down from $19.1 million in the same period last year.

How much did KalVista (KALV) raise in November 2024?

KalVista raised $160 million in aggregate gross proceeds through concurrent synthetic royalty financing and equity offerings.